These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37573615)

  • 21. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.
    Sun Y; Song S; Zhang Y; Mo W; Zhang X; Wang N; Xia Y; Tse G; Liu Y
    ESC Heart Fail; 2022 Feb; 9(1):667-675. PubMed ID: 34779134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction.
    Fu M; Pivodic A; Käck O; Costa-Scharplatz M; Dahlström U; Lund LH
    Clin Res Cardiol; 2023 Jan; 112(1):167-174. PubMed ID: 36443599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
    Xiang B; Zhang R; Wu X; Zhou X
    JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
    Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
    JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
    Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Tang J; Wang P; Liu C; Peng J; Liu Y; Ma Q
    Chin Med J (Engl); 2024 May; ():. PubMed ID: 38811344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
    Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis.
    Xiang B; Yu Z; Zhou X
    Front Cardiovasc Med; 2021; 8():787810. PubMed ID: 35097007
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
    Janse RJ; Fu EL; Dahlström U; Benson L; Lindholm B; van Diepen M; Dekker FW; Lund LH; Carrero JJ; Savarese G
    Eur J Heart Fail; 2022 Nov; 24(11):2185-2195. PubMed ID: 35851740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.
    Mukhopadhyay A; Reynolds HR; Nagler AR; Phillips LM; Horwitz LI; Katz SD; Blecker S
    BMC Cardiovasc Disord; 2022 Aug; 22(1):354. PubMed ID: 35927632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
    Aimo A; Vergaro G; Castiglione V; Rapezzi C; Emdin M
    Eur J Intern Med; 2020 Oct; 80():66-72. PubMed ID: 32475765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases.
    Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM
    PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
    Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M
    ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study.
    Bitar S; Thilly N; Agrinier N
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.